Abstract:Abstract: Antitumor activity of butein has been studied in various tumor types, but its potency in non-small cell lung cancer (NSCLC) is rarely known. Here, A549 and H1650 cells were treated with various concentrations of butein at different time points, the proliferation was evaluated by MTS and soft agar assay. What′s more, the activation of EGFR signaling pathway after butein treatment was tested via immunoblotting. Flow cytometry was conducted to assess cell cycle progression. The data showed that butein inhibited the proliferation of A549 and H1650 cells in a dose-dependent manner. Butein treatment not only suppressed the phosphorylation of EGFR signaling pathway, but also resulted in down-regulation of total EGFR expression level, as well as EGFR expression on membrane and in nucleus. Additionally, the phosphorylation levels of AuroraA/B and H3-S10 were inhibited after butein exposure, and flow cytometry data demonstrated that butein induced G2/M cell cycle arrest. These data indicate that butein inhibits human NSCLC via directly targeting EGFR and AuroraA/B signaling pathways.
引用本文:
李 伟, 刘文斌, 刘海丹. 紫铆因靶向EGFR和AuroraA/B信号通路抑制非小细胞肺癌的研究[J]. 生命科学研究, 2016, 20(5): 418-423.
LI Wei, LIU Wen-Bin, LIU Hai-Dan. Butein Inhibits Non-Small Cell Lung Cancer via Directly Targeting EGFR and AuroraA/B Signaling Pathways. Life Science Research, 2016, 20(5): 418-423.